TSX:DHT.UN - Post by User
Post by
Betteryear2on Aug 25, 2021 7:10am
142 Views
Post# 33759926
up to $135 Million Debt and Royalty Transaction
up to $135 Million Debt and Royalty TransactionSEATTLE and TORONTO, Aug. 25, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) (CTI) and DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (DRI) today announced transactions totaling up to $135 million in funding for CTI, with $50 million in secured debt to be funded at closing and $60 million to purchase a tiered royalty on sales of pacrinitib upon product approval of pacrinitib by the U.S. Food and Drug Administration (FDA). The proceeds of the transactions will be used by CTI to fund the commercialization of pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia. CTI has a New Drug Application (NDA) under priority review by FDA with a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2021, and is preparing for a potential commercial launch by end of year. https://www.prnewswire.com/news-releases/cti-biopharma-and-dri-healthcare-trust-announce-up-to-135-million-debt-and-royalty-transaction-301362310.html